WO2002060421A2 - Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence - Google Patents

Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence Download PDF

Info

Publication number
WO2002060421A2
WO2002060421A2 PCT/EP2002/000311 EP0200311W WO02060421A2 WO 2002060421 A2 WO2002060421 A2 WO 2002060421A2 EP 0200311 W EP0200311 W EP 0200311W WO 02060421 A2 WO02060421 A2 WO 02060421A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
amino
ethanol
methanesulphonamidophenyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/000311
Other languages
French (fr)
Other versions
WO2002060421A3 (en
Inventor
Pascal Pouzet
Franz Esser
Hisato Kitagawa
Naoki Ishiguro
Ikunobu Muramatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02710006A priority Critical patent/EP1363614B1/en
Priority to EA200300789A priority patent/EA200300789A1/en
Priority to MXPA03006816A priority patent/MXPA03006816A/en
Priority to CA002434565A priority patent/CA2434565A1/en
Priority to BR0206854-0A priority patent/BR0206854A/en
Priority to KR10-2003-7010204A priority patent/KR20030075173A/en
Priority to DK02710006T priority patent/DK1363614T3/en
Priority to SK977-2003A priority patent/SK9772003A3/en
Priority to IL15673002A priority patent/IL156730A0/en
Priority to EEP200300357A priority patent/EE200300357A/en
Priority to AT02710006T priority patent/ATE293966T1/en
Priority to JP2002560614A priority patent/JP2004517158A/en
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to PL02361731A priority patent/PL361731A1/en
Priority to HU0302752A priority patent/HUP0302752A2/en
Priority to DE60203882T priority patent/DE60203882T2/en
Publication of WO2002060421A2 publication Critical patent/WO2002060421A2/en
Publication of WO2002060421A3 publication Critical patent/WO2002060421A3/en
Priority to NO20033428A priority patent/NO20033428L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
    • C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to medicaments containing 2-amino-1-(4-hydroxy-2- methanesulphonamidophenyl)ethanol, one of the two optical isomers thereof and/or the pharmacologically acceptable salts thereof, particularly for treating urinary incontinence.
  • incontinence is meant an involuntary release of urine, i.e. weakness of the bladder.
  • the various manifestations of urinary incontinence include urge incontinence, reflex incontinence, overflow incontinence and stress incontinence.
  • the most common form of urinary incontinence is stress incontinence. This affects Women, in particular, after more or less difficult childbirth. The reason for this is that pregnancy and labour easily lead to a weakening of the pelvic floor.
  • Other causes of incontinence may lie, for example, in damage to the nerves of the pelvic floor, a congenitally short urethra or damage to the sphincter muscle.
  • alpha-1 L-agonists in the treatment of urinary incontinence, as they act selectively on the adrenoreceptors of the bladder and thus have a crucial effect on the tonicity of the urethra, without significantly affecting the cardiac circulatory system.
  • EP 0 538 469 describes 2-amino-1-(2-fluoro-5-methanesulphonamido- phenyl)ethanol and the use thereof for treating urinary incontinence.
  • the aim is therefore to develop a medicament with which urinary incontinence can be treated in a controlled manner.
  • a further objective is to develop medicaments which act selectively on the contractile mechanisms of the bladder without seriously affecting other organs such as e.g. peripheral blood vessels.
  • Another objective is to develop a medicament for treating urinary incontinence, in particular stress urinary incontinence, which has a relatively long-lasting effect.
  • Another objective is to develop a method of treating urinary incontinence, in particular stress urinary incontinence.
  • a drug which can be administered orally should be developed.
  • a further aim is to develop a non-toxic drug with few side-effects.
  • the overall aim of the present invention is therefore to find an active substance having the profiles described above and to develop a suitable medicament therefrom.
  • the enantiomerically pure forms of the compound i.e. the R- or S- form are not known as pharmaceutical substances. Also not known is the use of the compound, as a racemate or in enantiomerically pure form, i.e. in the R- or S- form, in a pharmaceutical composition for treating urinary incontinence, in particular stress urinary incontinence.
  • the compound is used in a pharmaceutical composition in the form of the racemate or one of the pure enantiomers.
  • the substance may be used both as a free base and as an acid addition salt.
  • salts are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid or organic acids such as acetic acid, citric acid, tartaric acid, malic acid, succinic acid, fumaric acid, p- toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid, lactic acid, ascorbic acid et cetera.
  • the hydrochloride is preferably used.
  • the compound according to the invention may be administered as a medicament by oral route, by inhalation, intranasally, intravenously, by subcutaneous, intramuscularily, transdermally, vaginalily or as a suppository. Oral administration is preferred.
  • the compound may be administered on its own or in conjunction with other appropriate active substances.
  • various parameters have to be taken into consideration, such as the age and body weight of the patient, and the nature and stage of the complaint.
  • the preferred dose for humans is between 0.001 mg and 1 g per day, preferably between 0.001 mg and 500 mg and most preferably between 0.01 mg and 100 mg and most preferably between 0.01 mg and 10 mg.
  • the total daily dose may be taken in one go or in several portions depending on the treatment regimen.
  • the treatment regimen may also prescribe intervals of more than one day between doses of the drug.
  • the active substance according to the invention may be administered orally in various formulations, e.g. as a solid, in liquid form, as a powder, in the form of tablets, as a coated tablet, sugar-coated tablets, as an oral disintegrating tablet, as a sublingual tablet, in a capsule, in granulated form, as a suspension, solution, emulsion, elixir or syrup, in the form of drops or in other forms.
  • various formulations e.g. as a solid, in liquid form, as a powder, in the form of tablets, as a coated tablet, sugar-coated tablets, as an oral disintegrating tablet, as a sublingual tablet, in a capsule, in granulated form, as a suspension, solution, emulsion, elixir or syrup, in the form of drops or in other forms.
  • Capsules may be produced, starting from a powder of the kind mentioned above or other powders, which are packed into a capsule, preferably a gelatine capsule. It is also possible to introduce lubricants known from the prior art into the capsule or to use them to seal the two halves of the capsule.
  • the dissolution rate of a capsule can be increased by the addition of disintegrant or solubilising substances, such as, for example, carboxymethylcellulose, carboxymethylcellulose calcium, lowly-substituted hydroxypropylcellulose, calcium carbonate, sodium carbonate, sodium carboxymethyl starch, crospovidone, croscarmellose sodium and other substances.
  • the active substance may be contained in the capsule not only as a solid but also in solution or in suspension, e.g. in vegetable oil, polyethyleneglycol or glycerol, using surfactants, etc.
  • Tablets may be prepared in which the powdered mixture is processed to form granules, mixed with other substances if necessary and then further compressed, for example.
  • the tablets may contain various excipients, e.g. starches, lactose, sucrose, glucose, sodium chloride, urea for soluble or injectable tablets, amylose, various types of cellulose as described above, etc. Glycerol or starch may be added, for example, as moisture retaining agents.
  • Starch alginic acid, calcium alginate, pectic acid, powdered agar-agar, formaldehyde gelatine, calcium carbonate, sodium bicarbonate, magnesium peroxide and amylose, for example, may be used as disintegrants.
  • Sucrose, stearin, solid paraffin (preferably with a melting point in the range from ⁇ 50-52X), cocoa butter and hydrogenated fats may be used as anti-disintegrants or solution retardants.
  • Suitable resorption accelerators include, inter alia, quaternary ammonium compounds, sodium lauryl sulphate, saponines.
  • Ether may be used as a binder distributor, for example, and cetylalcohol, glycerol monostearate, starch, lactose, wetting agents (e.g. Aerosol OT, Pluronics, Tweens) etc. may be used as hydrophilisers. or breakdown accelerators
  • tablet-making excipients in general: Aerosil, Aerosol OT ethylcellulose, Amberlite resin, XE-88, Amijel, Amisterol, amylose, Avicel microcrystalline-cellulose, bentonite, calcium sulphate, Carbowax 4000 and 6000, carrageenin, castor wax, cellulose, microcrystalline cellulose, dextrane, dextrin, base for pharmaceutical tablets, kaolin, spray dried lactose (USP), lactosil, magnesium stearate, mannitol, mannitol granular N. F.
  • Aerosil Aerosol OT ethylcellulose
  • Amberlite resin Amberlite resin
  • XE-88 Amberlite resin
  • Amijel Amisterol
  • amylose Avicel microcrystalline-cellulose
  • bentonite calcium sulphate
  • Carbowax 4000 and 6000 carrageenin
  • castor wax castor wax
  • cellulose microcrystalline cellulose
  • dextrane
  • methylcellulose Miglyol 812 neutral oil, powdered milk, lactose, nal-tab, Nepol- amylose, Pofizer crystalline sorbitol, plasdone, polyethyleneglycols, polyvinylpyrrolidone, Precirol, calves' foot oil (hydrogenated), base for melting tablets, silicones, stabiline, Sta-rx 1500, Syloid, Waldhof tablet base, Tablettol, talcum cetylatum and stearatum, Tego metal soaps, dextrose and tylose.
  • the tabletting adjuvant K (M25) is particularly preferred and also meets the requirements of the following pharmacopoeias: DAB, Ph, Eur, BP and NF.
  • the tablets may be produced by direct compression.
  • formulations suitable for oral administration may also be prepared, such as suspensions, solutions, emulsions, syrups, elixirs, etc. If desired, the compound may be microencapsulated.
  • a powder may be prepared, for example, by reducing the particles of active substance to a suitable size by grinding.
  • Diluted powders may be prepared by finely grinding the powdered substance with a non-toxic carrier such as lactose and producing it as a powder.
  • a non-toxic carrier such as lactose
  • Other carrier materials which are suitable for this purpose are other carbohydrates such as starch or mannitol.
  • these powders may contain flavourings, preservatives, dispersants, colourings and other pharmaceutically excipients.
  • the compound may be administered parenterally by dissolving, emulsifying or suspending it in a liquid and injecting it by subcutaneous, intramuscular or intravenous route.
  • Suitable solvents include, for example, water or oily media.
  • the compound may be formulated with low-melting and water-soluble or water-insoluble materials such polyethyleneglycol, cocoa butter, higher esters (e.g. myristyl palmitate) or mixtures thereof.
  • water-soluble or water-insoluble materials such polyethyleneglycol, cocoa butter, higher esters (e.g. myristyl palmitate) or mixtures thereof.
  • Preparation The active substance is mixed with some of the excipients and granulated in the usual way. The granules are sieved, combined with the remaining excipients and compressed into tablets weighing 180 mg.
  • racemic compound 5
  • the racemic compound can be prepared according to the procedures disclosed in GB 993,584 or US 3,341 ,584.
  • the pure enantiomers of the compound of the present invention can be obtained 10 f.e. by transforming them into an diasteriomeric salt, f.e. with tartaric acid or others as mentioned above, followed by separating the two diastereomeric salts from each other via crystallisation and then liberating the pure enantiomer as the free base by adding a strong amino-base or an alkali-hydroxide.
  • Still another way is to transform the racemic mixture into diastereomers, f.e. the diastereomeric salts as described above, to separate the two different -v diastereomers, diastereomeric salts respectively and then to liberate the pure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to medicaments containing 2-amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol, one of the two optical isomers thereof and/or the pharmacologically acceptable salts thereof, particularly for treating urinary incontinence

Description

Use of 2-amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
The present invention relates to medicaments containing 2-amino-1-(4-hydroxy-2- methanesulphonamidophenyl)ethanol, one of the two optical isomers thereof and/or the pharmacologically acceptable salts thereof, particularly for treating urinary incontinence.
The compound according to the invention has the following structure: Formula I:
Figure imgf000002_0001
Prior art:
By incontinence is meant an involuntary release of urine, i.e. weakness of the bladder. The various manifestations of urinary incontinence include urge incontinence, reflex incontinence, overflow incontinence and stress incontinence. The most common form of urinary incontinence is stress incontinence. This affects Women, in particular, after more or less difficult childbirth. The reason for this is that pregnancy and labour easily lead to a weakening of the pelvic floor. Other causes of incontinence may lie, for example, in damage to the nerves of the pelvic floor, a congenitally short urethra or damage to the sphincter muscle.
According to WO 96/32939 it is beneficial to use alpha-1 L-agonists in the treatment of urinary incontinence, as they act selectively on the adrenoreceptors of the bladder and thus have a crucial effect on the tonicity of the urethra, without significantly affecting the cardiac circulatory system. EP 0 538 469 describes 2-amino-1-(2-fluoro-5-methanesulphonamido- phenyl)ethanol and the use thereof for treating urinary incontinence.
Description of the invention Surprisingly, it has now been found that the compound of formula I has an outstanding agonistic effect on alpha-1 L-receptors. The substance acts highly selectively on the bladder and inhibits urinary urgency.
The aim is therefore to develop a medicament with which urinary incontinence can be treated in a controlled manner.
A further objective is to develop medicaments which act selectively on the contractile mechanisms of the bladder without seriously affecting other organs such as e.g. peripheral blood vessels.
Another objective is to develop a medicament for treating urinary incontinence, in particular stress urinary incontinence, which has a relatively long-lasting effect.
Another objective is to develop a method of treating urinary incontinence, in particular stress urinary incontinence.
Preferably, a drug which can be administered orally should be developed.
A further aim is to develop a non-toxic drug with few side-effects.
The overall aim of the present invention is therefore to find an active substance having the profiles described above and to develop a suitable medicament therefrom. Detailed description of the invention
The racemate of the compound according to the invention has been known since the 1960s.
It is described, for example, in US Patent 3,341 ,584 or GB 993,584. These publications mention that the racemate has a stimulant effect on alpha- and/or beta-receptors. The Journal of Medicinal Chemistry 10 (1967) page 467 describes an alpha-adrenergic effect.
The enantiomerically pure forms of the compound, i.e. the R- or S- form are not known as pharmaceutical substances. Also not known is the use of the compound, as a racemate or in enantiomerically pure form, i.e. in the R- or S- form, in a pharmaceutical composition for treating urinary incontinence, in particular stress urinary incontinence.
The compound is used in a pharmaceutical composition in the form of the racemate or one of the pure enantiomers.
The substance may be used both as a free base and as an acid addition salt. Examples of such salts are salts of inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid or organic acids such as acetic acid, citric acid, tartaric acid, malic acid, succinic acid, fumaric acid, p- toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid, lactic acid, ascorbic acid et cetera. The hydrochloride is preferably used.
The compound according to the invention may be administered as a medicament by oral route, by inhalation, intranasally, intravenously, by subcutaneous, intramuscularily, transdermally, vaginalily or as a suppository. Oral administration is preferred.
The compound may be administered on its own or in conjunction with other appropriate active substances. To determine the optimum dose of the active substance for urinary incontinence, various parameters have to be taken into consideration, such as the age and body weight of the patient, and the nature and stage of the complaint.
The preferred dose for humans is between 0.001 mg and 1 g per day, preferably between 0.001 mg and 500 mg and most preferably between 0.01 mg and 100 mg and most preferably between 0.01 mg and 10 mg.
In some cases a smaller amount may be sufficient, whereas in other cases a larger total amount may be needed.
The total daily dose may be taken in one go or in several portions depending on the treatment regimen. The treatment regimen may also prescribe intervals of more than one day between doses of the drug.
The active substance according to the invention may be administered orally in various formulations, e.g. as a solid, in liquid form, as a powder, in the form of tablets, as a coated tablet, sugar-coated tablets, as an oral disintegrating tablet, as a sublingual tablet, in a capsule, in granulated form, as a suspension, solution, emulsion, elixir or syrup, in the form of drops or in other forms.
Capsules may be produced, starting from a powder of the kind mentioned above or other powders, which are packed into a capsule, preferably a gelatine capsule. It is also possible to introduce lubricants known from the prior art into the capsule or to use them to seal the two halves of the capsule. The dissolution rate of a capsule can be increased by the addition of disintegrant or solubilising substances, such as, for example, carboxymethylcellulose, carboxymethylcellulose calcium, lowly-substituted hydroxypropylcellulose, calcium carbonate, sodium carbonate, sodium carboxymethyl starch, crospovidone, croscarmellose sodium and other substances. The active substance may be contained in the capsule not only as a solid but also in solution or in suspension, e.g. in vegetable oil, polyethyleneglycol or glycerol, using surfactants, etc.
Tablets (including vaginal tablets) may be prepared in which the powdered mixture is processed to form granules, mixed with other substances if necessary and then further compressed, for example. The tablets may contain various excipients, e.g. starches, lactose, sucrose, glucose, sodium chloride, urea for soluble or injectable tablets, amylose, various types of cellulose as described above, etc. Glycerol or starch may be added, for example, as moisture retaining agents.
Starch, alginic acid, calcium alginate, pectic acid, powdered agar-agar, formaldehyde gelatine, calcium carbonate, sodium bicarbonate, magnesium peroxide and amylose, for example, may be used as disintegrants.
Sucrose, stearin, solid paraffin (preferably with a melting point in the range from ■ 50-52X), cocoa butter and hydrogenated fats may be used as anti-disintegrants or solution retardants.
Suitable resorption accelerators include, inter alia, quaternary ammonium compounds, sodium lauryl sulphate, saponines.
Ether may be used as a binder distributor, for example, and cetylalcohol, glycerol monostearate, starch, lactose, wetting agents (e.g. Aerosol OT, Pluronics, Tweens) etc. may be used as hydrophilisers. or breakdown accelerators
Moreover, the following may be considered as tablet-making excipients in general: Aerosil, Aerosol OT ethylcellulose, Amberlite resin, XE-88, Amijel, Amisterol, amylose, Avicel microcrystalline-cellulose, bentonite, calcium sulphate, Carbowax 4000 and 6000, carrageenin, castor wax, cellulose, microcrystalline cellulose, dextrane, dextrin, base for pharmaceutical tablets, kaolin, spray dried lactose (USP), lactosil, magnesium stearate, mannitol, mannitol granular N. F. methylcellulose, Miglyol 812 neutral oil, powdered milk, lactose, nal-tab, Nepol- amylose, Pofizer crystalline sorbitol, plasdone, polyethyleneglycols, polyvinylpyrrolidone, Precirol, calves' foot oil (hydrogenated), base for melting tablets, silicones, stabiline, Sta-rx 1500, Syloid, Waldhof tablet base, Tablettol, talcum cetylatum and stearatum, Tego metal soaps, dextrose and tylose. The tabletting adjuvant K (M25) is particularly preferred and also meets the requirements of the following pharmacopoeias: DAB, Ph, Eur, BP and NF.
Other excipients from the prior art may also be used.
The tablets may be produced by direct compression.
Other formulations suitable for oral administration may also be prepared, such as suspensions, solutions, emulsions, syrups, elixirs, etc. If desired, the compound may be microencapsulated.
A powder may be prepared, for example, by reducing the particles of active substance to a suitable size by grinding. v
Diluted powders may be prepared by finely grinding the powdered substance with a non-toxic carrier such as lactose and producing it as a powder. Other carrier materials which are suitable for this purpose are other carbohydrates such as starch or mannitol. If desired, these powders may contain flavourings, preservatives, dispersants, colourings and other pharmaceutically excipients.
The compound may be administered parenterally by dissolving, emulsifying or suspending it in a liquid and injecting it by subcutaneous, intramuscular or intravenous route. Suitable solvents include, for example, water or oily media.
To prepare suppositories the compound may be formulated with low-melting and water-soluble or water-insoluble materials such polyethyleneglycol, cocoa butter, higher esters (e.g. myristyl palmitate) or mixtures thereof. Examples
1. Metabolism
To determine the metabolism the enzyme CYP2D6 was allowed to act on the hydrochloride of the compound according to the invention. After 30 minutes a check was made to determine how much of the substance had been broken down by the enzyme. (-)-R-2-Amino-1-(2-fluoro-5-methanesulphonamido-phenyl)ethanol 2 was used as a comparison.
Figure imgf000008_0001
2. Efficacy and selectivity The efficacy and selectivity of the compound according to the invention is determined as follows, using the same findings as described in 1 :
Figure imgf000008_0002
Maximum contraction in the dog and activity on human urethra are percentages of contraction compared with noradrenaline.
Selectivity in the dog is the difference obtained from the percentage contraction of the dog's femoral artery at 10"5 M and percentage contraction of the carotid artery in the dog at 10"5 M. 3. Pharmaceutical Composition Example A: Tablets
2-amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol 1 mg Lactose 105 mg
Microcrystaline cellulose 30 mg
Corn starch 30 mg
Povidon 5 mg
Sodium carboxymethyl starch 5 mg Colloidal silica 3 mg
Magnesium stearate 1 mg
Total 180 mg
Preparation: The active substance is mixed with some of the excipients and granulated in the usual way. The granules are sieved, combined with the remaining excipients and compressed into tablets weighing 180 mg.
Example B: Ampoules
2-amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol 1.0 mg Sodium chloride 18.0 mg
Sufficient water for injection to make up to 2.0 ml
Preparation: The active substance and sodium chloride are dissolved in water for injection and transferred into glass ampoules in an aseptic condition.
Example C: Capsules
2-amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol 1 mg
Lactose 178 mg
Magnesium stearate 1 mg Total 180 mg Preparation: The active substance is mixed with the excipients and filled into capsules as known in the state of the art.
Preparation of the racemic compound: 5 The racemic compound can be prepared according to the procedures disclosed in GB 993,584 or US 3,341 ,584.
Preparation of the enantiomeric pure forms
The pure enantiomers of the compound of the present invention can be obtained 10 f.e. by transforming them into an diasteriomeric salt, f.e. with tartaric acid or others as mentioned above, followed by separating the two diastereomeric salts from each other via crystallisation and then liberating the pure enantiomer as the free base by adding a strong amino-base or an alkali-hydroxide.
15 Another way to obtain the pure enantiomers is purifying the racemate via HPLC by using a chiral column.
Still another way is to transform the racemic mixture into diastereomers, f.e. the diastereomeric salts as described above, to separate the two different -v diastereomers, diastereomeric salts respectively and then to liberate the pure
20. enantiomer again.
All separation procedures as such are well known in the art.

Claims

Patent Claims
1. R-2-Amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol or a pharmacologically acceptable salt thereof for preparing a medicament.
2. S-2-Amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol or a pharmacologically acceptable salt thereof for preparing a medicament.
3. Compound according to one of claims 1 or 2, characterised in that the pharmacologically acceptable salt is the hydrochloride.
4. Pharmaceutical composition containing a compound according to one of claims 1 to 3.
5. Pharmaceutical composition containing a compound according to one of <, claims 1 to 3 in an amount of between 0.001 mg and 1 g per day, preferably between 0.001 mg and 500 mg and most preferably between 0.01 mg and 100 mg and most preferably between 0.01 mg and 10 mg.
6. Pharmaceutical composition according to claim 4 or 5 in the form of a tablet, or a capsule.
7. Use of a compound selected from R-2-Amino-1-(4-hydroxy-2- methanesulphonamidophenyl)ethanol, S-2-Amino-1-(4-hydroxy-2- methanesulphonamidophenyl)ethanol and/or the racemate thereof or a pharmaceutically acceptable salt thereof, preferably the hydrochloride or a pharmaceutical preparation comprising such a compound in an amount according to claim 5 or in an application form according to claim 6 for preparing a medicament for treating urinary incontinence, in particular stress urinary incontinence.
8. Use according to claim 7, characterised in that the compound contains only R-2-Amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol or a pharmaceutically acceptable salt thereof but not the S-form thereof.
9. Use according to claim 7, characterised in that the compound contains only S- 2-Amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol or a pharmaceutically acceptable salt thereof but not the R-form thereof.
10. Use according to claim 7, characterised in that the compound contains the racemate or a pharmaceutically acceptable salt thereof.
11. Use of a compound according to any of claims 7 to 10 for oral administration.
12. Use of a compound according to any of claims 7 to 10 for transdermal, parenteral, rectal or vaginal administration.
13. Method of treating urinary incontinence, in particular stress urinary incontinence, by applying a compound selected from R-2-Amino-1-(4-hydrαxy- 2-methanesulphonamidophenyl)ethanol, S-2-Amino-1-(4-hydroxy-2- methanesulphonamidophenyl)ethanol and/or the racemate thereof or a pharmaceutically acceptable salt thereof, preferably the hydrochloride or a pharmaceutical preparation comprising such a compound in an amount according to claim 5 or in an application form according to claim 6.
14. Method according to claim 13, whereby the administration route of the compound or pharmaceutical preparation is orally.
15. Method according to claim 13, whereby the administration route of the compound or pharmaceutical preparation is a transdermal, parenteral, rectal or vaginal administration.
PCT/EP2002/000311 2001-02-01 2002-01-15 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence Ceased WO2002060421A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AT02710006T ATE293966T1 (en) 2001-02-01 2002-01-15 USE OF 2-AMINO-1-(4-HYDROXY-3-METHANESULPHONAMIDOPHENYL)ETHANOL FOR THE TREATMENT OF URINARY INCONTINENCE
MXPA03006816A MXPA03006816A (en) 2001-02-01 2002-01-15 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence.
CA002434565A CA2434565A1 (en) 2001-02-01 2002-01-15 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
BR0206854-0A BR0206854A (en) 2001-02-01 2002-01-15 Use of 2-amino-1- (4-hydroxy-2-methanesulfonamidophenyl) ethanol for the treatment of urinary incontinence
KR10-2003-7010204A KR20030075173A (en) 2001-02-01 2002-01-15 Use of 2-amino-1-(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
DK02710006T DK1363614T3 (en) 2001-02-01 2002-01-15 Use of 2-amino-1- (4-hydroxy-3-methanesulfonamidophenyl) ethanol in the treatment of urinary incontinence
SK977-2003A SK9772003A3 (en) 2001-02-01 2002-01-15 R- and S-enantiomer of 2-amino-1- (4-hydroxy-3-methanesulfonamidophenyl) ethanol, pharmaceutical composition containing them and their use
IL15673002A IL156730A0 (en) 2001-02-01 2002-01-15 Use of 2-amino-1 (4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
EEP200300357A EE200300357A (en) 2001-02-01 2002-01-15 Use of 2-amino-1- (4-hydroxy-3-methanesulfonamidophenyl) -ethanol for the treatment of urinary incontinence
EP02710006A EP1363614B1 (en) 2001-02-01 2002-01-15 Use of 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol for treating urinary incontinence
EA200300789A EA200300789A1 (en) 2001-02-01 2002-01-15 APPLICATION OF 2-AMINO-1- (4-HYDROXY-3-METHESULPHONE-AMIDOPHENYL) ETHANOL FOR THE TREATMENT OF URINARY HOLDING
JP2002560614A JP2004517158A (en) 2001-02-01 2002-01-15 Use of 2-amino-1- (4-hydroxy-2-methanesulfonamidophenyl) ethanol to treat urinary incontinence
PL02361731A PL361731A1 (en) 2001-02-01 2002-01-15 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
HU0302752A HUP0302752A2 (en) 2001-02-01 2002-01-15 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence and pharmaceutical composition containing the same
DE60203882T DE60203882T2 (en) 2001-02-01 2002-01-15 USE OF 2-AMINO-1- (4-HYDROXY-3-METHANESULPHONAMIDOPHENYL) ETHANOL FOR THE TREATMENT OF HARNINE CONTINENCE
NO20033428A NO20033428L (en) 2001-02-01 2003-07-31 Use of 2-amino-1 (4-hydroxy-3-methanesulfonamidophenyl) ethanol for the treatment of urinary incontinence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10104369.4 2001-02-01
DE10104369A DE10104369A1 (en) 2001-02-01 2001-02-01 Use of 2-amino- (4-hydroxy-2-methanesulfonamidophenyl) ethanol for the treatment of urinary incontinence

Publications (2)

Publication Number Publication Date
WO2002060421A2 true WO2002060421A2 (en) 2002-08-08
WO2002060421A3 WO2002060421A3 (en) 2002-12-19

Family

ID=7672382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000311 Ceased WO2002060421A2 (en) 2001-02-01 2002-01-15 Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence

Country Status (26)

Country Link
EP (1) EP1363614B1 (en)
JP (1) JP2004517158A (en)
KR (1) KR20030075173A (en)
CN (1) CN1489459A (en)
AR (1) AR035778A1 (en)
AT (1) ATE293966T1 (en)
BG (1) BG108033A (en)
BR (1) BR0206854A (en)
CA (1) CA2434565A1 (en)
CZ (1) CZ20032097A3 (en)
DE (2) DE10104369A1 (en)
DK (1) DK1363614T3 (en)
EA (1) EA200300789A1 (en)
EC (1) ECSP034684A (en)
EE (1) EE200300357A (en)
ES (1) ES2240708T3 (en)
HU (1) HUP0302752A2 (en)
IL (1) IL156730A0 (en)
MX (1) MXPA03006816A (en)
NO (1) NO20033428L (en)
PL (1) PL361731A1 (en)
PT (1) PT1363614E (en)
SK (1) SK9772003A3 (en)
UY (1) UY27145A1 (en)
WO (1) WO2002060421A2 (en)
ZA (1) ZA200305201B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046664A1 (en) * 2003-11-04 2005-05-26 Boehringer Ingelheim International Gmbh Pharmaceutical composition consisting of a beta-3 adrenoceptor agonist and an alpha agonist
US12447241B2 (en) 2013-08-19 2025-10-21 Taris Biomedical Llc Multi-unit drug delivery devices and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US341584A (en) * 1886-05-11 Device foe
GB993584A (en) * 1962-01-24
DK0538469T3 (en) * 1990-02-07 1996-01-15 Nippon Shinyaku Co Ltd Sulfonanilide derivative and drug
DE19514579A1 (en) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Use of alpha-1-olone agonists for the treatment of urinary incontinence
WO1996038143A1 (en) * 1995-06-02 1996-12-05 Synaptic Pharmaceutical Corporation The use of alpha-1c-selective adrenoceptor agonists for the treatment of urinary incontinence
FR2737494B1 (en) * 1995-08-04 1997-08-29 Synthelabo BENZENESULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2000010557A1 (en) * 1998-08-25 2000-03-02 Nippon Shinyaku Co.,Ltd. Stabilized solid preparations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046664A1 (en) * 2003-11-04 2005-05-26 Boehringer Ingelheim International Gmbh Pharmaceutical composition consisting of a beta-3 adrenoceptor agonist and an alpha agonist
JP2007509897A (en) * 2003-11-04 2007-04-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition comprising β-3-adrenoceptor agonist and α-agonist
US12447241B2 (en) 2013-08-19 2025-10-21 Taris Biomedical Llc Multi-unit drug delivery devices and methods

Also Published As

Publication number Publication date
AR035778A1 (en) 2004-07-14
EE200300357A (en) 2003-10-15
PL361731A1 (en) 2004-10-04
CN1489459A (en) 2004-04-14
BG108033A (en) 2004-12-30
IL156730A0 (en) 2004-02-08
DE60203882T2 (en) 2006-02-02
CZ20032097A3 (en) 2003-12-17
DE60203882D1 (en) 2005-06-02
PT1363614E (en) 2005-06-30
ZA200305201B (en) 2004-05-17
CA2434565A1 (en) 2002-08-08
KR20030075173A (en) 2003-09-22
EP1363614A2 (en) 2003-11-26
UY27145A1 (en) 2002-08-30
HUP0302752A2 (en) 2003-11-28
NO20033428L (en) 2003-09-30
ATE293966T1 (en) 2005-05-15
BR0206854A (en) 2004-01-13
SK9772003A3 (en) 2005-03-04
ES2240708T3 (en) 2005-10-16
WO2002060421A3 (en) 2002-12-19
DK1363614T3 (en) 2005-05-30
EP1363614B1 (en) 2005-04-27
JP2004517158A (en) 2004-06-10
ECSP034684A (en) 2003-08-29
MXPA03006816A (en) 2004-05-14
DE10104369A1 (en) 2002-08-08
NO20033428D0 (en) 2003-07-31
EA200300789A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
US20070155679A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
ZA200503282B (en) Pharmaceutical composition comrpising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
RU2715734C2 (en) S1p modulator immediate release dosage regimen
HRP970519A2 (en) Medical treatment
IE881477L (en) Pharmaceutical compositions
WO2002060428A2 (en) Methods of using and compositions comprising (-)sibutramine optionally in combination with other pharmacologically active compounds
EP1363614B1 (en) Use of 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol for treating urinary incontinence
US6660772B2 (en) Use of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol for treating urinary incontinence
AU2002228045A1 (en) Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence
EP2517728B1 (en) Olmesartan medoxomil for preventing or treating angiogenic eye diseases
EP1333028A1 (en) 2&#39;-Halo-3&#39;,5&#39;-dialkoxyphen-1&#39;-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
SK14552001A3 (en) Osanetant in the treatment of mood disorders
EP2146713B1 (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas
KR20010021796A (en) Treatment and Prevention of Cardiac Disorders Using Selective Serotonin Re-uptake Inhibitors (SSRI)
EA003584B1 (en) A method for promoting smoking cessation or reduction or preventing relapse smoking and use of paroxetine or a pharmaceutically acceptable salt or solvate to produce a medicament
EP2526949B1 (en) Agents for treating migraine
US6703409B2 (en) 2′-Halo-3′,5′-dialkoxyphen-1′-yl-imino-2-imidazolidine and the use thereof as a drug
MXPA00010343A (en) Treatment of generalized anxiety disorder with paroxetine
CZ20003885A3 (en) Use of paroxetine and pharmaceutical composition
JPH10218772A (en) Agent for preventing / treating motivation, spontaneous decline or depressive symptoms due to cerebrovascular disorder
KR20080026115A (en) Pharmaceutical composition for treating anorexia nervosa comprising 1- (3-chlorophenyl) -3-alkylpiperazine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500681

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2002710006

Country of ref document: EP

Ref document number: 156730

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1033/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003/05201

Country of ref document: ZA

Ref document number: 200305201

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2434565

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1200300645

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 10803302

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P-600/03

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006816

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: P20030621A

Country of ref document: HR

Ref document number: 02804407X

Country of ref document: CN

Ref document number: 2002560614

Country of ref document: JP

Ref document number: 9772003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2003-2097

Country of ref document: CZ

Ref document number: 1020037010204

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200300789

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002228045

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 527841

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020037010204

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2002710006

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2097

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2003-2097

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002710006

Country of ref document: EP